Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.30 and traded as high as $3.50. Sonoma Pharmaceuticals shares last traded at $3.10, with a volume of 811,769 shares changing hands.

Sonoma Pharmaceuticals Trading Down 3.0 %

The company has a market cap of $3.49 million, a price-to-earnings ratio of -0.52 and a beta of 1.38. The business has a 50-day moving average price of $3.10 and a 200 day moving average price of $1.32.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.